169 related articles for article (PubMed ID: 12430859)
1. A novel therapeutic approach for hematological malignancies based on cellular differentiation and apoptosis.
Kizaki M; Nakazato T; Ito K; Kawamura C; Miyakawa Y; Ikeda Y
Int J Hematol; 2002 Aug; 76 Suppl 1():250-2. PubMed ID: 12430859
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis induced by molecular targeting therapy in hematological malignancies.
Adachi S; Leoni LM; Carson DA; Nakahata T
Acta Haematol; 2004; 111(1-2):107-23. PubMed ID: 14646349
[TBL] [Abstract][Full Text] [Related]
3. [Oral molecular targeting agents in hematological malignancy].
Wakabayashi S; Ohashi K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1214-8. PubMed ID: 20647701
[TBL] [Abstract][Full Text] [Related]
4. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Jakubowska J; Stasiak M; Szulawska A; Bednarek A; Czyz M
Acta Biochim Pol; 2007; 54(4):839-46. PubMed ID: 17957275
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
7. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis.
Jakubowska J; Wasowska-Lukawska M; Czyz M
Eur J Pharmacol; 2008 Oct; 596(1-3):41-9. PubMed ID: 18782571
[TBL] [Abstract][Full Text] [Related]
8. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
9. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets and the treatment of myeloid leukemia.
Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
[TBL] [Abstract][Full Text] [Related]
11. Rhein augments ATRA-induced differentiation of acute promyelocytic leukemia cells.
Heo SK; Noh EK; Kim JY; Jegal S; Jeong Y; Cheon J; Koh S; Baek JH; Min YJ; Choi Y; Jo JC
Phytomedicine; 2018 Oct; 49():66-74. PubMed ID: 30217263
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
13. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
14. STI571: targeting BCR-ABL as therapy for CML.
Mauro MJ; Druker BJ
Oncologist; 2001; 6(3):233-8. PubMed ID: 11423669
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
16. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.
van Gils N; Verhagen HJMP; Smit L
Exp Hematol; 2017 Aug; 52():12-23. PubMed ID: 28456748
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
18. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
[TBL] [Abstract][Full Text] [Related]
19. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
20. [Advances in the target therapy of hematological malignancies].
Niu T; Liu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):642-6. PubMed ID: 25286692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]